LY3002813-IV + LY3002813-SC + Placebo-IV
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer Disease
Conditions
Alzheimer Disease
Trial Timeline
May 3, 2013 → Aug 24, 2016
NCT ID
NCT01837641About LY3002813-IV + LY3002813-SC + Placebo-IV
LY3002813-IV + LY3002813-SC + Placebo-IV is a phase 1 stage product being developed by Eli Lilly for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01837641. Target conditions include Alzheimer Disease.
What happened to similar drugs?
20 of 20 similar drugs in Alzheimer Disease were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01837641 | Phase 1 | Completed |
Competing Products
20 competing products in Alzheimer Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 21 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 32 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 40 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 35 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 35 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 35 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 47 |
| GSK4527226 | Alector | Phase 2 | 29 |
| AL002 + Placebo | Alector | Phase 2 | 25 |
| GSK4527226 | Alector | Phase 2 | 32 |
| AL002 | Alector | Phase 2 | 17 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| donanemab | Eli Lilly | Phase 2 | 35 |
| ATH-1017 | LeonaBio | Phase 2/3 | 20 |
| ATH-1017 + Placebo | LeonaBio | Phase 2/3 | 28 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 25 |
| NDX-1017 + Placebo | LeonaBio | Phase 1 | 19 |
| simufilam | Cassava Sciences | Phase 2 | 17 |
| 50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125 | Cassava Sciences | Phase 1 | 19 |